The additional benefit of closed-loop insulin delivery in individuals with well controlled type 1 diabetes (ie, HbA1c <7·5%) is the reduction of the residual risk of complications, hypoglycaemia, and glycaemic variability, as well as the burden of self-management. This evidence concerns the gene INS and type 1 diabetes mellitus.